Which countries have approved Extra Super Zhewitra for use?

Extra Super Zhewitra is a medication that contains two active ingredients: Vardenafil and Dapoxetine. Vardenafil is used to treat erectile dysfunction (ED), while Dapoxetine is used to treat premature ejaculation (PE). The approval and availability of Extra Super Zhewitra may vary by country, as regulatory agencies in different countries have their own processes for approving medications for use. However, both Vardenafil and Dapoxetine are approved for use in several countries around the world for the treatment of ED and PE, respectively. Vardenafil, the active ingredient in Extra Super Zhewitra, is commonly marketed under the brand name Levitra and is approved for use in various countries, including the United States, European Union member states, Canada, Australia, and many others. Dapoxetine, the other active ingredient in Extra Super Zhewitra, is marketed under various brand names, including Priligy, and is approved for use in numerous countries for the treatment of PE. Some of the countries where Dapoxetine is approved for use include the United States, European Union member states, Canada, Australia, and many others. As for the combination medication Extra Super Zhewitra specifically, its approval and availability may vary depending on the regulatory requirements and decisions of individual countries' health authorities. It's essential to consult with a healthcare professional or regulatory authority in your country to determine whether Extra Super Zhewitra is approved for use and available for purchase.